(Q40197990)

English

A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma

scientific article published on 29 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 September 2017

A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma (English)

1 reference

Europe PubMed Central

18 September 2017

multicenter clinical trial

0 references

0 references

cyclic permutation

0 references

author name string

Chuanying Geng

1

1 reference

Europe PubMed Central

18 September 2017

Jian Hou

2

1 reference

Europe PubMed Central

18 September 2017

Yaozhong Zhao

3

1 reference

Europe PubMed Central

18 September 2017

Xiaoyan Ke

4

1 reference

Europe PubMed Central

18 September 2017

Zhao Wang

5

1 reference

Europe PubMed Central

18 September 2017

Lugui Qiu

6

1 reference

Europe PubMed Central

18 September 2017

Hao Xi

7

1 reference

Europe PubMed Central

18 September 2017

Fuxu Wang

8

1 reference

Europe PubMed Central

18 September 2017

Na Wei

9

1 reference

Europe PubMed Central

18 September 2017

Yan Liu

10

1 reference

Europe PubMed Central

18 September 2017

Shifang Yang

11

1 reference

Europe PubMed Central

18 September 2017

Peng Wei

12

1 reference

Europe PubMed Central

18 September 2017

Xiangjun Zheng

13

1 reference

Europe PubMed Central

18 September 2017

Zhongxia Huang

14

1 reference

Europe PubMed Central

18 September 2017

Bing Zhu

15

1 reference

Europe PubMed Central

18 September 2017

Wen-Ming Chen

16

1 reference

Europe PubMed Central

18 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 September 2014

1 reference

Europe PubMed Central

18 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

18 September 2017

89

1 reference

Europe PubMed Central

18 September 2017

11

1 reference

Europe PubMed Central

18 September 2017

1037-1042

1 reference

Europe PubMed Central

18 September 2017

Multiple myeloma : recent progress in diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Treatment options for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Identification and characterization of a new member of the TNF family that induces apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

The TRAIL apoptotic pathway in cancer onset, progression and therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

New insights into apoptosis signaling by Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Death receptor agonists as a targeted therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Targeting apoptosis proteins in hematological malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Is TRAIL hepatotoxic?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23822

21 January 2018

Identifiers

10.1002/AJH.23822

1 reference

Europe PubMed Central

18 September 2017

1 reference

Europe PubMed Central

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40197990&oldid=1888570260"